XS-1017
| Project Name | XS-1017 |
| Mechanism of Action | p53-mdm2 Inhibitor |
| Registration Category | Category 1 of Chemical Drugs |
| Origin | Independently Developed |
| Project Progress | Completed preclinical research including target design, compound screening and design, optimization of compounds, activity and toxicology tests, process development, and patent filing |
| Field |
Anticancer Drugs |
| Patent Status | Authorized |
| Indications | Main development indications for drugs with the same mechanism: Acute Myeloid Leukemia (AML); Potential Future Indications: Solid tumors, Polycythemia Vera, Primary Thrombocythemia, Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), Soft Tissue Sarcoma, Melanoma, etc. |
YY2201
| Project Name | YY2201 |
| Mechanism of Action | ATR Inhibitor |
| Registration Category | Category 1 of Chemical Drugs |
| Origin | Independently Developed |
| Project Progress | We have completed target design, compound screening and design, CMC (Chemistry, Manufacturing, and Controls) research, non-clinical pharmacology and toxicology trials, patent applications, and IND (Investigational New Drug) submissions in both China and the US. We have obtained clinical approval, passed the ethics review, and are preparing to conduct Phase I clinical trials. |
| Field |
Anticancer Drugs |
| Patent Status | Accepted |
| Indications | Hematologic malignancies with ATM gene mutations (such as Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, etc.), Solid tumors (such as Lung Cancer, Ovarian Cancer, Breast Cancer, Colorectal Cancer, etc.) |
